168,893 Shares in MiMedx Group, Inc $MDXG Bought by Ieq Capital LLC

Ieq Capital LLC bought a new stake in MiMedx Group, Inc (NASDAQ:MDXG) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 168,893 shares of the company’s stock, valued at approximately $650,000. Ieq Capital LLC owned 0.12% of MiMedx Group as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of MDXG. BlackRock Inc. bought a new position in shares of MiMedx Group in the 2nd quarter worth about $46,795,000. Nantahala Capital Management LLC acquired a new position in shares of MiMedx Group in the 3rd quarter valued at about $10,237,000. Marshall Wace LLP boosted its position in shares of MiMedx Group by 864.9% during the 4th quarter. Marshall Wace LLP now owns 1,381,288 shares of the company’s stock valued at $9,351,000 after purchasing an additional 1,238,132 shares in the last quarter. Hillsdale Investment Management Inc. bought a new stake in shares of MiMedx Group during the 4th quarter valued at about $7,134,000. Finally, Disciplined Growth Investors Inc. MN boosted its position in shares of MiMedx Group by 283.0% during the 3rd quarter. Disciplined Growth Investors Inc. MN now owns 1,383,451 shares of the company’s stock valued at $9,656,000 after purchasing an additional 1,022,202 shares in the last quarter. Institutional investors own 79.15% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Seaport Research Partners downgraded MiMedx Group to a “neutral” rating in a report on Monday, August 17th. Wall Street Zen upgraded MiMedx Group from a “sell” rating to a “hold” rating in a report on Saturday. Raymond James Financial set a $8.00 price objective on shares of MiMedx Group in a research note on Monday, August 17th. Craig Hallum lifted their price objective on shares of MiMedx Group from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Thursday. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $8.00 target price on shares of MiMedx Group in a research report on Monday, August 17th. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.57.

MiMedx Group Trading Down 0.2%

Shares of MiMedx Group stock opened at $4.50 on Friday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.79 and a current ratio of 5.33. MiMedx Group, Inc has a 52 week low of $3.03 and a 52 week high of $7.97. The stock has a 50 day moving average price of $4.18 and a two-hundred day moving average price of $4.09. The stock has a market capitalization of $655.92 million, a PE ratio of 112.53 and a beta of 1.45.

MiMedx Group (NASDAQ:MDXG) last issued its earnings results on Wednesday, July 29th. The company reported ($0.05) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.05). MiMedx Group had a return on equity of 12.09% and a net margin of 1.76%.The company had revenue of $64.36 million for the quarter, compared to analyst estimates of $63.46 million. As a group, equities analysts anticipate that MiMedx Group, Inc will post -0.1 earnings per share for the current fiscal year.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.